SOUTH SAN FRANCISCO, Calif. — August 7, 2025 — Leads & Copy — Sutro Biopharma, Inc. (NASDAQ: STRO) announced its second quarter 2025 financial results and recent business highlights, including progress on its pipeline of novel antibody drug conjugates (ADCs) and a research collaboration with the FDA to advance regulatory standards for ADCs.
The company is on track to initiate a first-in-human study with STRO-004, a potential best-in-class Tissue Factor ADC, in the second half of 2025. Preclinical data across the pipeline, including STRO-006 and dual-payload ADCs, has expanded. Greg Chow has been appointed as Chief Financial Officer. Cash, cash equivalents, and marketable securities totaled $205.1 million as of June 30, 2025, providing a cash runway into early 2027.
Sutro’s CEO, Jane Chung, said the company made strong progress advancing its pipeline of novel ADCs in the second quarter, including preparing to initiate a clinical trial for STRO-004. Chung also highlighted the unique capabilities of Sutro’s platform technology.
Sutro is progressing its wholly-owned dual-payload ADC platform, with an IND filing anticipated in 2027. Two research and development programs are progressing under Sutro’s collaboration with Astellas focused on dual-payload immunostimulatory ADCs (iADCs), including one program that recently entered an IND-enabling toxicology study. Ipsen decided not to advance the STRO-003 program under its partnership with Sutro.
Emily White, Sutro Biopharma, (650) 823-7681, ewhite@sutrobio.com
Amy Bonanno, Lyra Strategic Advisory, abonanno@lyraadvisory.com
